» Articles » PMID: 24077325

Cytochrome C Release in Acute Myocardial Infarction Predicts Poor Prognosis and Myocardial Reperfusion on Contrast-enhanced Magnetic Resonance Imaging

Overview
Date 2013 Oct 1
PMID 24077325
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Myocardial ischemia and reperfusion injury in ST-segment elevation myocardial infarction (STEMI) can trigger no-flow, resulting in myocardial necrosis and apoptosis, even a poor prognosis. Cytochrome c can induce an apoptotic process. The aim of our study was to assess the relationship between systemic cytochrome c levels and the occurrence of no-reflow in STEMI.

Methods: One hundred and sixty patients with STEMI undergoing a primary percutaneous coronary intervention (PPCI) were randomly chosen. Patients were divided into two groups defined by the mean cytochrome c peak level after PPCI. No-reflow was assessed using three different methods after PPCI: myocardial blush grade, electrocardiographic ST-resolution, and microvascular obstruction (MO) assessed by cardiovascular magnetic resonance imaging. The primary clinical end points were major adverse cardiovascular events (defined as cardiac death, reinfarction, or new congestive heart failure). Clinical follow-up was carried out for 1 year.

Results: Patients with a cytochrome c level of at least the mean peak level had a greater creatine kinase-MB isoenzyme peak level (P=0.044), a lower left ventricular ejection fraction (P=0.029), a significantly higher occurrence of early MO (P=0.008), and a significantly larger extent of early MO (P=0.020). The cytochrome c peak level was elevated in patients with early MO (P=0.025), myocardial blush grade 0-1 (P=0.002), and ST-resolution less than 30% (P=0.003) after PPCI. A higher incidence of cardiac death at the 1-year follow-up was found in the patients with cytochrome c levels of at least the mean peak level (log rank, P=0.029).

Conclusion: Cytochrome c levels above the mean peak level were related to no-reflow and mortality in patients with STEMI.

Citing Articles

Mitochondrial Damage-associated Molecular Patterns as Potential Biomarkers in DCD Heart Transplantation: Lessons From Myocardial Infarction and Cardiac Arrest.

Longnus S, Rutishauser N, Gillespie M, Reichlin T, Carrel T, Sanz M Transplant Direct. 2021; 8(1):e1265.

PMID: 34934807 PMC: 8683216. DOI: 10.1097/TXD.0000000000001265.


SCD leads to the development and progression of acute myocardial infarction through the AMPK signaling pathway.

Wang L, Yu F BMC Cardiovasc Disord. 2021; 21(1):197.

PMID: 33879068 PMC: 8059031. DOI: 10.1186/s12872-021-02011-8.


Mitochondrial Biomarkers in Patients with ST-Elevation Myocardial Infarction and Their Potential Prognostic Implications: A Prospective Observational Study.

Cosentino N, Campodonico J, Moltrasio M, Lucci C, Milazzo V, Rubino M J Clin Med. 2021; 10(2).

PMID: 33451159 PMC: 7828727. DOI: 10.3390/jcm10020275.


Effects of Serum Cytochrome c on Contrast-Induced Nephropathy in Patients with ST-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention.

Tang C, Hou J, Yan G, Qiao Y, Wang D, Zhu B Biomed Res Int. 2019; 2019:9357203.

PMID: 30809550 PMC: 6364113. DOI: 10.1155/2019/9357203.


Diagnostic and Prognostic Utility of Circulating Cytochrome c in Acute Myocardial Infarction.

Marenzi G, Cosentino N, Boeddinghaus J, Trinei M, Giorgio M, Milazzo V Circ Res. 2016; 119(12):1339-1346.

PMID: 27799252 PMC: 5627527. DOI: 10.1161/CIRCRESAHA.116.309792.